MoU Signed For Commercial Production of Lumpi-ProVac: Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year. According to the Scientists and Government, the vaccine technology will meet out the standard of the market and significantly provide a defence mechanism to control the devastating lumpy skin disease.
LSD: Livelihood Crisis for India’s Small Dairy Farmers
Why In News?
- An MoU for production of Goat Pox vaccine and “Lumpi-ProVac” vaccine was signed in Nagpur on 29th December, 2022.
- Lumpi-ProVac for LSD is ICAR developed indigenous vaccine.
Background Of LSD
- The Lumpy Skin Disease has been reported in India from 2019 while first case was reported in the state of Odisha. After that, it has spread to multiple states in the country.
- From 2019-2022, death of a large number of cattle has been reported from different states with high morbidity especially in North-West region of the country.
- The disease has been controlled and contained with the available Goatpox vaccine in the country.
- Considering the heavy production losses and mortality of sizable number of cattle, ICAR initiated research on development of indigenous homologous vaccine against Lumpy Skin Disease.
Presently Which Vaccine Is Used To Treat LSD?
- At present Goat Pox vaccine is used for controlling Lumpy Skin Disease in animals and this has been proven effective against Lumpy.
- This recent MoU will also ensure large-scale production of Goat Pox vaccine for future needs of India’s livestock sector.
Who Developed Lumpi-ProVac Vaccine For LSD
National Centre for Veterinary Type Culture, ICAR-National Research Centre on Equines (ICAR-NRCE), Hisar (Haryana), in collaboration with ICAR-Indian Veterinary Research Institute (IVRI), Izatnagar (UP) developed a homologous live-attenuated LSD vaccine, named Lumpi-ProVacInd.
Who Granted Rights for Commercial production of “Lumpi-ProVac”?
Agrinnovate India Limitd (AgIn), the commercial arm of DARE, Ministry of Agriculture and Farmers’ Welfare, Govt. of India granted “Non-Exclusive Rights” for Commercial production of “Lumpi-ProVac”, to Institute of Veterinary Biological Products (IVBP).
Key Features Of Lumpi-ProVac
- Use: Lumpi-ProVac Vaccine is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year.
- Safety: Lumpi-ProVac is safe in animals and induces LSDV-specific antibody-and cell-mediated immune response, besides providing complete protection against lethal LSDV challenge.
- Dose: A single dose of the vaccine contains 103.5 TCID50 of live-attenuated LSDV (Ranchi strain).
- Storage: The vaccine is stored at 4°C. The vaccine must be shipped on ice and must be used within a few hours after reconstitution.
- Patent: The patent has been filed by the ICAR for the technology.
Recent Science and Technology Current Affairs Articles:
